IP Library Granted Patent US 8,124,778
Granted Patent B2
US 8,124,778 · App. 12/600,736 · Granted Feb 28, 2012

Tricyclic inhibitors of fatty acid amide hydrolase

Assignee: The Scripps Research Institute
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,124,778
App. No.
12/600,736
Granted
Feb 28, 2012
Kind
B2
Abstract

A series of substituted oxazole compounds having an alpha keto side chain at the 2 position and an aromatic, heteroaromatic or heterocycle substituent at the 5 position are disclosed. These compounds exhibit inhibition of fatty acid amid hydrolase and arc useful for treatment of malconditions involving that enzyme.

Claims (31)

1. A compound having the following structure:

wherein Ar is a phenyl or pyridyl having a carbon as its point of attachment to the oxazole;

R 1 is independently selected from the group consisting of hydrogen, —(C 1 -C 6 alkyl), —(C 3 -C 6 alkyl), —CF 3 , —CN, —C(O)C 1 -C 4 alkyl optionally substituted with one, two, or three fluoro substituents, —CO 2 (C 1 -C 4 alkyl), —CO 2 H, —C(O)N(R a )R b , —OH, —O(C 1 -C 6 alkyl), halo, —NO 2 , —NR a R b , —N(R a )C(O)R b , —N(R a )SO 2 R b , —SO 2 N(R a )R b , —SR a , —S(O)R a , and —SO 2 R a ;

where R a and R b are each independently selected from the group consisting of —H, —(C 1 -C 6 alkyl), and —(C 3 -C 6 cycloalkyl); and

R 2 is independently selected from the group consisting of hydrogen, —(C 1 -C 6 alkyl), —(C 3 -C 6 alkyl), —CF 3 , —CN, —C(O)C 1 -C 4 alkyl optionally substituted with one, two, or three fluoro substituents, —CO 2 (C 1 -C 4 alkyl), —CO 2 H, —C(O)N(R c )R d , —OH, —O(C 1 -C 6 alkyl), -halo, —NO 2 , —NR c R d , —N(R c )C(O)R d , —N(R c )SO 2 R d , —SO 2 N(R c )R d , —SR C , —S(O)R C , —SO 2 R c ;

where R c and R d are each independently selected from the group consisting of —H, —(C 1 -C 6 alkyl), and —(C 3 -C 6 cycloalkyl); and

Ar 1 is selected from the group consisting of:

X is selected from the group of diradicals consisting of —CH 2 —, —O—, —S—, —S(O)—, —S(O) 2 —, —NR 5 —, —CH(OH)—, and —C(O)NH—; and

R 3 is selected from the group consisting of —NHBOC, —Cl, —Br, —I, —NH 2 , —NO 2 , —O(C 1 -C 6 alkyl), —S(C 1 -C 6 alkyl), —S(O)(C 1 -C 6 alkyl), —S(O) 2 (C 1 -C 6 alkyl), —CF 3 , —COOH, and —CO 2 (C 1 -C 6 alkyl);

R 4 is selected from the group consisting of —H, —NHBOC, —Cl, —Br, —I, —NH 2 , —NO 2 , —O(C 1 -C 6 alkyl), —S(C 1 -C 6 alkyl), —S(O)(C 1 -C 6 alkyl), —S(O) 2 (C 1 -C 6 alkyl), —CF 3 , —COOH, and —CO 2 (C 1 -C 6 alkyl); and

R 5 is selected from the group consisting —H, and —(C 1 -C 6 alkyl); and

Z is selected from the group of diradicals consisting of —O—, —S—, and —NR 5 —; and

m is an integer between 0 and 6; and

n is an integer between 0 and 6;

with the following provisos:

if m is 0, then n cannot be 0; and

if X is —CH 2 —, then Ar 1 cannot be phenyl;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 , wherein Ar is selected from the group consisting of the following

3. A compound according to claim 1 , wherein R 1 is selected from the group consisting of —CH 3 , —CF 3 , —CN, —C(O)CF 3 , —CO 2 CH 3 , —CO 2 H, —C(O)NH 2 , —OH, —OCH 3 , —F, —NO 2 , —NH 2 , and —SO 2 NH 2 .

4. A compound according to claim 1 , wherein R 2 is —H.

5. A compound according to claim 2 , wherein R 1 is selected from the group consisting of —CH 3 , —CF 3 , —CN, —C(O)CF 3 , —CO 2 CH 3 , —CO 2 H, —C(O)NH 2 , —OH, —OCH 3 , —F, —NO 2 , —NH 2 , and —SO 2 NH 2 .

6. A compound according to claim 2 , wherein R 2 is —H.

7. A compound according to claim 2 , wherein R 1 is selected from the group consisting of —CH 3 , —CF 3 , —CN, —C(O)CF 3 , —CO 2 CH 3 , —CO 2 H, —C(O)NH 2 , —OH, —OCH 3 , —F, —NO 2 , —NH 2 , and —SO 2 NH 2 .

8. A compound according to claim 2 , wherein R 2 is —H.

9. A compound according to claim 7 , wherein R 2 is —H.

10. A compound according to claim 1 , having the following structure:

11. A compound according to claim 10 , having any of the following structures, or a pharmaceutically acceptable salt thereof:

12. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

13. A pharmaceutical combination comprising a compound of claim 1 in combination with another FAAH modulator or another biologically active agent.

14. A pharmaceutical combination of claim 13 wherein the active ingredient is an opiod, an NSAID, gabapentin, pregabalin, tramadol, acetaminophen or aspirin.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2011
From: BOGER, DALE L.
To: SCRIPPS RESEARCH INSITUTE, THE
Reel/Frame 026296/0080 →
CONFIRMATORY LICENSE Recorded Dec 15, 2009
From: SCRIPPS RESEARCH INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 023655/0431 →
Continuity (2)
Provisional Application 60932494 · May 31, 2007
Related Publication 20100216750A1 · Aug 26, 2010